Manuscripts

Schneider T, Bergqvist A, Wang JT, Wagg A, Ebel Bitoun C. Treatment with fesoterodine or tolterodine reduces symptom bother in elderly patients with overactive
bladder including urgency urinary incontinence. Presented at: The 27th Annual Meeting
of The European Association of Urology; February 24-28, 2012; Paris, France.

Wagg, Adrian, Vik Khullar, Martin C. Michel, Matthias Oelke, Amanda Darekar, and Caty Ebel Bitoun. "Long−term safety, tolerability and efficacy of flexible−dose fesoterodine in elderly patients with overactive bladder: Open−label extension of the SOFIA trial." Neurourology and urodynamics 33, no. 1 (2014): 106-114.

Adrian Wagg, MD,Vik Khullar, MD, Daniela Marschall-Kehrel, MD,Martin C. Michel, MD, Matthias Oelke, MD,Amanda Darekar, MSc, Caty E. Bitoun, MD, David Weinstein, MSc, and Ian Osterloh, MBBS. Flexible-dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial. J Am Geriatr Soc 2013 Jan 25th; Epub ahead of print. DOI: 10.1111/jgs.12088

Linda Cardozo & Timothy Hall & John Ryan & Caty Ebel Bitoun & Imran Kausar & Amanda Darekar & Adrian Wagg Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation Int Urogynecol J DOI 10.1007/s00192-012-1804-1

Cardozo J, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A, Wagg A. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights
into factors associated with dose escalation. Int Urogynecol J. 2012;Epub.

Coyne KS, Sexton CC, Kopp ZS, Ebel Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in

the UK and Sweden: results from EpiLUTS. BJU Int. 2011;Epub.

Wagg A, Khullar V, Marshall-Kehrel D, Michel MC, Oelke M, Tincello D, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Assessment of Fesoterodine Treatment in Older People With Overactive Bladder: Results of SOFIA, a Double-Blind, Placebo-Controlled Pan European Trial. Eur Urol Suppl. 2011:10(2):276-277

Wagg, Adrian, Vik Khullar, Daniela Marschall−Kehrel, Martin C. Michel, Matthias Oelke, Amanda Darekar, Caty E. Bitoun, David Weinstein, and Ian Osterloh. "Flexible−Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double−Blind, Placebo−Controlled Study of Fesoterodine in an Aging Population Trial." Journal of the American Geriatrics Society 61, no. 2 (2013): 185-193.

Khullar V, Kelleher CJ, Ebel Bitoun C, Arumi D, Whelan L, Cardozo L. Utilization of the Self-Assessment Goal Achievement Questionnaire to Evaluate the Importance of Treatment Goals in Subjects With Overactive Bladder Symptoms. Int Urogyn J. 2010:21(1):545-546.27.

Linda Cardozo & Timothy Hall & John Ryan & Caty Ebel Bitoun & Imran Kausar & Amanda Darekar & Adrian Wagg Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation Int Urogynecol J DOI 10.1007/s00192-012-1804-1

Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urol. 2008;54:543-562.

Wagg A, Khullar V, Marshall-Kehrel D, Michel MC, Oelke M, Darekar A, Ebel Bitoun C, Osterloh I. Efficacy and Tolerability of Fesoterodine in Older Subjects With Overactive Bladder: Results of SOFIA. J Am Geriatr Soc. 2011:9(Suppl 1):S124

ABSTRACTS & POSTERS

EBEL BITOUN CATY CAN ICT SUPPORT ENHANCE QUALITY OF HUMAN INTERACTION IN OUR DAY TO DAY LIVING?
Presented at the 10th World Conference of Gerontechnology September 28-30 Nice, France

Schneider T, Bergqvist A, Wang JT, Wagg A, Ebel Bitoun C. Treatment with fesoterodine or tolterodine reduces symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. Presented at: The 27th Annual Meeting
of The European Association of Urology; February 24-28, 2012; Paris, France.

Wagg A, Khullar V, Oelke M, Marschall-Kehrel D, Michel MC, Darekar A, Ebel Bitoun C, Bavendam T, Osterloh I. Effect of Treatment Response on the Decision to Escalate Antimuscarinic Dose in Elderly Subjects With Overactive Bladder. Presented at: The 27th
Annual Congress of The European Association of Urology; February 24–28, 2012; Paris, France.

Khullar V, Sexton CC, Thompson CL, Milsom I, Ebel Bitoun C, Coyne KS. The Relationship between BMI and Urinary Incontinence Subgroups: Results from EpiLUTS. Presented at: The 107th American Urological Association Annual Meeting; May 19-23, 2012; Atlanta, GA. (poster)

Khullar V, Sexton CC, Thompson CL, Milsom I, Ebel Bitoun C, Coyne KS. The Relationship between BMI and Urinary Incontinence Subgroups: Results from EpiLUTS. Presented at: The 107th American Urological Association Annual Meeting; May 19-23, 2012; Atlanta, GA. (PPT slides)

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Tincello DG, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Efficacy, Tolerability, and Patient-Reported

Outcomes in Older People With Overactive Bladder Treated With Fesoterodine: Results
of SOFIA, a Double-Blind, Placebo-Controlled Pan European Trial. Presented at:
The 106th Annual Meeting of the American Urological Association; May 14-19, 2011;
Washington, DC.

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Tincello DG, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Assessment of fesoterodine treatment in older people with overactive bladder: Results of SOFIA, a double-blind, placebo-controlled pan European trial. Presented at: The 26th Congress of The European Association of Urology; March 18-22, 2011; Vienna, Austria.

Wagg A, Khullar V, Marshall-Kehrel D, Michel MC, Oelke M, Darekar A, Ebel Bitoun C, Osterloh I. Efficacy and Tolerability of Fesoterodine in Older Subjects With Overactive Bladder: Results of SOFIA. Presented at: the Annual Scientific Meeting of The American Geriatric Society; May 11-14, 2011; National harbor, MD.

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Efficacy and Tolerability of Fesoterodine in Older People With Overactive Bladder: Results of the Open-Label Phase of the SOFIA Trial. Presented at: The 41st Meeting of the International Continence Society; August 29–September 2, 2011; Glasgow, UK. (abstract)

Cardozo L, Khullar V, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A, Whelan L, Wagg A. Effects of Drug Cessation in Subjects Receiving Fesoterodine for Treatment of Overactive Bladder Symptoms. Presented at: The 41st Meeting of the International Continence Society; August 29–September 2, 2011; Glasgow, UK. (abstract)

Cardozo L, Hall T, Ryan J, Ebel Bitoun C, Darekar A, Wagg A. Does Fesoterodine Provide Efficacy, Tolerability, and Treatment Satisfaction? A Study of British Patients With the Overactive Bladder Syndrome. Presented at: The 2010 Joint Annual Meeting of
ICS and IUGA; August 23–27, 2010; Toronto, ON, Canada.

Cardozo L, Khullar V, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A, Whelan L, Wagg A. Effects of Drug Cessation in Subjects Receiving Fesoterodine for Treatment of Overactive Bladder Symptoms. Presented at: The 41st Meeting of the International Continence Society; August 29–September 2, 2011; Glasgow, UK. (ppt slides)

Khullar V, Kelleher CJ, Ebel Bitoun C, Arumi D, Whelan L, Cardozo L. Utilization of the Self-Assessment Goal Achievement Questionnaire to Evaluate the Importance of Treatment Goals in Subjects With Overactive Bladder Symptoms. Presented at: The 2010 Joint Annual Meeting of ICS and IUGA; August 23–27, 2010; Toronto, ON, Canada

Breza J, Mišanko V, Maľa M, Zigová I, Ebel Bitoun C. Observational Study of Fesoterodine in Patients With Overactive Bladder Who Failed Previous Antimuscarinic Therapy. Presented at: The American Urological Association; May 29 - June 3, 2010; San Francisco, CA.

Castro Diaz D, Miranda P, Sanchez-Ballester F, Arumi D, Lizarraga I, Ebel Bitoun C, on behalf of the Spanish IMPACTA study group. Factors Predictive of Dissatisfaction With Overactive Bladder Treatment. Presented at: The 25th Annual Meeting of the European Association of Urology; April 16-20, 2010; Barcelona, Spain.

Breza J, Mišanko V, Maľa M, Zigová I, Bergqvist A, Ebel Bitoun C. Observational Study of Fesoterodine in Patients With Overactive Bladder Who Failed Previous Antimuscarinic
Therapy. Presented at: The 25th Annual Meeting of the European Association of Urology;
April 16-20, 2010; Barcelona, Spain.

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Tincello DG, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Patient-Reported Outcomes Show Fesoterodine is Effective in Older People for the Treatment of Overactive Bladder: Results of SOFIA, a
Pan European Trial. Presented at: The 25th Annual Meeting of the European Association
of Urology; April 16-20, 2010; Barcelona, Spain.

Coyne K, Sexton C, Weinstein D, Kopp Z, Chapple C, Ebel-Bitoun C, Milsom I, Kaplan S. THE IMPACT OF OAB ON MALE SEXUAL HEALTH: RESULTS FROM EPILUTS. Presented at: The 104th Annual Meeting of The American Urological Assocation; April 25-30, 2009; Chicago, Illinois.42.

Fianu-Jonasson A, Brubaker L,Kelleher C, Khullar V, Ebel Bitoun C, Weinstein D, Andersson AS, Piault-Louis E. Understanding Swedish Patients' Expectations for Treatment of Their Urinary Symptoms. Presented at: The Nordic Urogynecological Association Annual Meeting; May 14-16, 2009; Reykjavik, Iceland.

Coyne K, Sexton C, Weinstein D, Kopp Z, Ebel-Bitoun C, Milsom I, Wein A, Chapple C, on behalf of the EpiLUTS Team. THE PREVALENCE OF OAB IN THE US, UK, AND SWEDEN: RESULTS FROM EPILUTS. PRESENTED AT: The 104th Annual Meeting of The American Urological Assocation; April 25-30, 2009; Chicago, Illinois.

Coyne KS, Margolis MK, Weinstein D, Ebel-Bitoun C, Khullar V. Health-Related Quality of Life Differences Between Men and Women With OAB Treated With Fesoterodine. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (poster)

Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Safety and Tolerability of Antimuscarinic Treatments in Overactive Bladder: Results from an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (poster presentation)41

Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Safety and Tolerability of Antimuscarinic Treatments in Overactive Bladder: Results from an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (oral presentation)

Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Safety and Tolerability of Antimuscarinic Treatments in Overactive Bladder: Results from an

Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (abstract)

Khullar V, Chapple CR, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Patient-Perceived Effects of Antimuscarinic Treatment: Results From an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (oral presentation)

Khullar V, Chapple CR, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Patient-Perceived Effects of Antimuscarinic Treatment: Results From an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (poster)